DXCM Share Price Performance
US$90.14
15.84 (21.32%)
4.2% undervalued intrinsic discount
US$94.12
Fair Value
Price US$90.14
AnalystConsensusTarget US$94.12
AnalystLowTarget US$67.93
Fair ValueUS$94.12
Share Pricen/a
Narrative Update • Aug 15
DexCom, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 160 Fair Values set on narratives written by author
DXCM Community Narratives
AN
Fair Value
·Fair Value US$94.12 4.2% undervalued intrinsic discount
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
0users have liked this narrative
1users have commented on this narrative
77users have followed this narrative
AN
Fair Value
·Fair Value US$67.93 32.7% overvalued intrinsic discount
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DexCom
4.2% undervalued intrinsic discount
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
View narrativeAN
Updated 15 Aug
DexCom
32.7% overvalued intrinsic discount
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
View narrativeAN
Updated 26 Jun
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
DXCM: CONNECT Data And Type 2 Access Will Guide Balanced Outlook
Fair Value: US$94.12 4.2% undervalued intrinsic discount
77 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
DXCM: Future CGM Adoption And Trial Data Will Test Premium Expectations
Fair Value: US$67.93 32.7% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DexCom, Inc. Key Details
About DXCM
- Founded
- 1999
- Employees
- 11050
- CEO
- WebsiteView website
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
